Celltrion Strikes $278m Deal With Takeda
Korean Firm Expands In APAC, Small Molecules Via Takeda Asset Buy
Celltrion has bought a portfolio of selected products in the Asia-Pacific region from Takeda, marking a foray into small-molecule drugs.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Through a licensing-out deal with ORIC for its EGFR/HER2 exon-20 inhibitor, South Korea's Voronoi hopes to gain from its new partner's commercialization experience in NSCLC. The alliance aims to build a potentially best-in-class presence in a competitive landscape.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.